Quotient sets sights on $75m IPO
This article was originally published in Clinica
Scottish firm Quotient, which specializes in blood transfusion diagnostics, is hoping to raise up to $75m in an initial public offering. The Midlothian company plans to list on the Nasdaq under the ticker symbol QTNT; it didn’t give details of how many shares it plans to sell or at what price. Founded in 2007, Quotient booked sales of $14.4m and made a net loss of $4.7m during the fiscal year ended 31 March 2013.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.